Literature DB >> 5257391

Pompe's disease.

G R Hogan, L Gutmann, R Schmidt, E Gilbert.   

Abstract

Mesh：

Substances：

Year:  1969        PMID： 5257391     DOI： 10.1212/wnl.19.9.894

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  16 in total

1.  Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice.

Authors:  Kai Qiu; Darin J Falk; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

3.  Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle.

Authors:  J J Martin; T de Barsy; F van Hoof; G Palladini
Journal:  Acta Neuropathol       Date:  1973-02-19       Impact factor: 17.088

4.  The symptomatology, morphology and biochemistry of glycogenosis type II (Pompe) in the adult.

Authors:  G K Schlenska; R Heene; G Spalke; D Seiler
Journal:  J Neurol       Date:  1976-06-14       Impact factor: 4.849

Review 5.  The respiratory neuromuscular system in Pompe disease.

Authors:  David D Fuller; Mai K ElMallah; Barbara K Smith; Manuela Corti; Lee Ann Lawson; Darin J Falk; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2013-06-21       Impact factor: 1.931

6.  Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation.

Authors:  E Ponce; D P Witte; R Hirschhorn; M L Huie; G A Grabowski
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 7.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

8.  Pompe's Disease in Childhood: A Metabolic Myopathy.

Authors:  U Raju; S C Shaw; K S Rana; M Sharma; H R Ramamurthy
Journal:  Med J Armed Forces India       Date:  2011-07-21

9.  Neural deficits contribute to respiratory insufficiency in Pompe disease.

Authors:  Lara R DeRuisseau; David D Fuller; Kai Qiu; Keith C DeRuisseau; William H Donnelly; Cathryn Mah; Paul J Reier; Barry J Byrne
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

10.  Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.

Authors:  Darin J Falk; Cathryn S Mah; Meghan S Soustek; Kun-Ze Lee; Mai K Elmallah; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.